April 12, 2012

Intellipharmaceutics Announces First Quarter 2012 Results

 

TORONTO, April 12, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 29, 2012. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

The Company recorded a loss for the three months ended February 29, 2012 of $1.9 million, or $0.12 per common share, compared with a loss of $2.7 million, or $0.22 per common share, for the three months ended February 28, 2011. The Company's decreased net loss in the first quarter ended February 29, 2012, can be attributed to the prior period's financing expense of $2.2 million partially offset by the prior period's fair value adjustment of derivative liability of $1.0 million. There was no comparable financing expense in the 2012 period; however during the 2012 period there was a fair value adjustment of derivative liability of $1.0 million related to the private placement financing completed on February 1, 2011. After adjusting for these items, the loss for the three months ended February 29, 2012 was higher by $1.4 million and is discussed below.

Loss from operations for the three months ended February 29, 2012 was $3.1 million compared with $1.8 million for the three months ended February 28, 2011. Research and development expense for the three months ended February 29, 2012 increased to $2.0 million compared to $1.2 million in the three months ended February 28, 2011. After adjusting for stock-based compensation expense, expenditures for research and development for the three months ended February 29, 2012 were higher by $0.2 million. Selling, general and administrative expenses for the three months ended February 29, 2012 increased to $1.1 million versus $0.5 million in the prior period. After adjusting for stock-based compensation expense, expenditures for selling, general and administrative expenses for the three months ended February 29, 2012 were higher by $0.1 million.

At February 29, 2012, Intellipharmaceutics' cash and cash equivalents totaled $2.6 million, compared with $4.8 million at November 30, 2011. The decrease in cash during the three months ended February 29, 2012 is mainly a result of cash used in operating activities related to research and development activities. The increase in cash during the three months ended February 28, 2011 is mainly the result of cash flows from financing activities. Subsequent to the end of the quarter, the Company raised an additional $5 million in gross proceeds discussed further below.

For the three months ended February 29, 2012 net cash flows used in operating activities increased to $2.2 million, as compared to net cash flows used in operating activities for the three months ended February 28, 2011 of $2.0 million. This increase is a result of higher expenditures in research and development activities as well as higher selling, general and administrative expenses during the three months ended February 29, 2012. For the three months ended February 28, 2011 net cash flows from financing activities of $11.7 million related mainly to the gross proceeds of $12.0 million from the issuance of shares and warrants from the private placement completed on February 1, 2011.

Corporate Update

  • In January 2012, Intellipharmaceutics announced the appointment of Ira Baeringer as the Vice President, Business Development of its wholly owned United States subsidiary, Intellipharmaceutics Ltd., effective February 1, 2012. Mr. Baeringer provides advice and assistance to Intellipharmaceutics with the commercialization of products in its controlled-release generic drug Abbreviated New Drug Application ("ANDA") portfolio and 505(b)(2) New Drug Application ("NDA") portfolio across markets inside and outside the United States. Mr. Baeringer brings 20 years of experience in pharmaceutical licensing, development, supply, acquisitions, divestitures, and alliance management. He was most recently with sanofi-aventis from 2009 to 2012, and was previously with Sandoz Inc., Dorland Sweeney Jones, Forest Pharmaceuticals, Inc. and TEVA Pharmaceuticals USA.
     
  • On March 15, 2012, Intellipharmaceutics announced the closing of a registered direct common share offering for gross proceeds of approximately $5 million. The Company sold an aggregate of 1,818,182 shares to U.S. institutional investors at a price of $2.75 per share. After placement agent fees and estimated offering expenses, the Company received net proceeds from the offering of approximately $4.4 million. Intellipharmaceutics intends to use the net proceeds to file additional ANDAs with the Food and Drug Administration ("FDA"), to advance clinical trials for its abuse resistant Rexista™ technology and/or other NDA 505(b)(2) opportunities, to establish additional partnerships, and for working capital, research, product development and general corporate purposes. 

Intellipharmaceutics' goals for 2012 include the following: 

  • Obtain FDA approval of Intellipharmaceutics' generic version of Focalin XR®
  • File up to two additional ANDAs with the FDA
  • Establish one or more additional development/marketing alliances
  • Schedule a pre-IND meeting with the FDA to discuss Rexista™ oxycodone clinical development plan
  • Complete manufacturing of clinical batches of Rexista™ oxycodone
  • Initiate Phase I studies using clinical batches of Rexista™ oxycodone 

About Intellipharmaceutics

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology, Intellipharmaceutics has a pipeline of product candidates in various stages of development, including six ANDAs under review by the FDA, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes, pain and infection.

Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements include, without limitation, statements expressed or implied regarding our plans and milestones, status of developments or expenditures relating to our business, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future sales and revenues, projected costs, and market penetration. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue," "intends," "could," or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the effects of general economic conditions, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors, including the current status of our product development programs, capital availability, the potential dilutive effects of any financing, the timing of our programs to research, develop and commercialize our product candidates, the timing, costs and uncertainties regarding obtaining regulatory approvals to market our product candidates, our estimates regarding our capital requirements and future revenues, the timing and amount of investment tax credits, and other risks and uncertainties detailed from time to time in our public disclosure documents or other filings with the securities commissions or other securities regulatory bodies in Canada and the U.S. Additional risks and uncertainties relating to us and our business can be found in the "Risk Factors" section of our latest annual information form and latest Form 20-F, as well as in our other public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The condensed unaudited interim consolidated financial statements, accompanying notes to the condensed unaudited interim consolidated financial statements, and Management Discussion and Analysis for the three months ended February 29, 2012, will be accessible on Intellipharmaceutics' Website at www.intellipharmaceutics.com and will be available on SEDAR and EDGAR.

Summary financial tables are provided below.

 
Intellipharmaceutics International Inc.
Condensed unaudited interim consolidated balance sheets
As at 
(Stated in U.S. dollars)
  February 29,
2012
November 30,
2011
   $   $ 
Assets    
Current     
Cash and cash equivalents  2,632,537  4,817,088
Accounts receivable  13,876  3,383
Investment tax credits  457,991  349,861
Prepaid expenses, sundry and other assets  194,261  124,982
   3,298,665  5,295,314
     
Deferred offering cost  159,750  --
Property and equipment, net   943,298  951,914
   4,401,713  6,247,228
     
Liabilities     
Current     
Accounts payable   349,548  554,210
Accrued liabilities   384,154  436,154
Employee cost payable   666,326  736,073
Current portion of capital lease obligations   46,389  43,383
Due to related parties   791,995  757,126
   2,238,412  2,526,946
     
Deferred revenue   --  107,091
Capital lease obligations   85,933  95,206
Warrant liability   5,611,609  6,611,015
   7,935,954  9,340,258
     
Shareholders' deficiency    
Capital stock     
Authorized    
Unlimited common shares without par value    
Unlimited preference shares    
Issued and outstanding    
15,933,444 common shares   147,152  147,152
(2011 - 15,908,444)    
Additional paid-in capital  22,512,912  20,822,672
Accumulated other comprehensive loss   (309,967)  (115,035)
Deficit  (25,884,338)  (23,947,819)
   (3,534,241)  (3,093,030)
   4,401,713  6,247,228
     
     
Intellipharmaceutics International Inc.
Condensed unaudited interim consolidated statements of operations 
and comprehensive loss
for the three months ended February 29, 2012 and February 28, 2011
(Stated in U.S. dollars)
     
  2012 2011
   $   $ 
     
Revenue    
Research and development  107,091  --
   107,091  --
     
Expenses    
Research and development   2,003,427  1,189,496
Selling, general and administrative  1,149,756  530,642
Depreciation  61,370  50,513
   3,214,553  1,770,651
     
Loss from operations  (3,107,462)  (1,770,651)
Fair value adjustment of derivative liabilty  968,181  1,035,070
Financing expense  --  (2,223,485)
Net foreign exchange gain  210,607  248,665
Interest income  8,630  10,189
Interest expense  (16,475)  (23,281)
Loss  (1,936,519)  (2,723,493)
Other comprehensive loss  
Foreign exchange translation adjustment  (194,932)  (224,923)
Comprehensive loss  (2,131,451)  (2,948,416)
     
Loss per common share, basic and diluted  (0.12)  (0.22)
     
Weighted average number of common shares outstanding, basic and diluted  15,929,323 12,355,943
     
Intellipharmaceutics International Inc.
Unaudited interim consolidated statements of cash flows
for the three months ended February 29, 2012 and February 28, 2011
(Stated in U.S. dollars)     
  2012 2011
   $   $ 
     
Loss   (1,936,519)  (2,723,493)
Items not affecting cash    
Depreciation  61,370  50,513
Stock-based compensation  1,589,843  462,739
Deferred share units  6,569  --
Interest accrual  11,301  23,305
Fair value adjustment of derivative liability   (968,181)  (1,035,070)
Financing expense  --  1,085,353
Unrealized foreign exchange (gain) loss  (197,421)  21,131
Change in non-cash operating assets & liabilities    
Accounts receivable  (10,482)  (60)
Investment tax credits  (97,289)  561,812
Prepaid expenses and sundry assets  (66,776)  (50,546)
Accounts payable and accrued liabilities  (482,723)  (399,051)
Deferred revenue  (107,091)  --
Cash flows used in operating activities  (2,197,399)  (2,003,367)
     
Financing activities    
Payments to related parties  --  (351,229)
Repayment of capital lease obligations  (10,585)  (5,657)
Issuance of common shares on exercise of stock options  --  90,818
Proceeds from issuance of shares and warrants, gross   --  12,000,000
Proceeds from issuance of shares on exercise of warrants   62,500  --
Cash flows provided from financing activities  51,915  11,733,932
     
Investing activity    
Purchase of property and equipment  (52,755)  (3,396)
Cash flows used in investing activities  (52,755)  (3,396)
     
Effect of foreign exchange gain on cash held in foreign currency  13,688  21,900
     
(Decrease) increase in cash  (2,184,551)  9,749,069
Cash, beginning of period  4,817,088  789,136
     
Cash and cash equivalents, end of period  2,632,537  10,538,205
     
Supplemental cash flow information    
Interest paid  --  113,940
Taxes paid  --  --
CONTACT: Intellipharmaceutics International Inc. 
         30 Worcester Road
         Toronto, ON Canada M9W 5X2
         www.intellipharmaceutics.com

         Shameze Rampertab
         Vice President Finance & CFO
         416-798-3001 x106
         investors@intellipharmaceutics.com


Close window | Back to top


Copyright 2017 Intellipharmaceutics